Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Martins MM, et al. Among authors: horiuchi d. Cancer Discov. 2015 Feb;5(2):154-67. doi: 10.1158/2159-8290.CD-14-0552. Epub 2014 Dec 12. Cancer Discov. 2015. PMID: 25501949 Free PMC article.
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion.
Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT. Huang TH, et al. Among authors: horiuchi d. J Biol Chem. 2009 Jul 3;284(27):18515-24. doi: 10.1074/jbc.M109.006676. Epub 2009 May 6. J Biol Chem. 2009. PMID: 19419954 Free PMC article.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Balko JM, et al. Among authors: horiuchi d. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. Cancer Discov. 2014. PMID: 24356096 Free PMC article.
Taking on challenging targets: making MYC druggable.
Horiuchi D, Anderton B, Goga A. Horiuchi D, et al. Am Soc Clin Oncol Educ Book. 2014:e497-502. doi: 10.14694/EdBook_AM.2014.34.e497. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857145 Free PMC article. Review.
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A. Horiuchi D, et al. Nat Med. 2016 Nov;22(11):1321-1329. doi: 10.1038/nm.4213. Epub 2016 Oct 24. Nat Med. 2016. PMID: 27775705 Free PMC article.
S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.
Begg LR, Orriols AM, Zannikou M, Yeh C, Vadlamani P, Kanojia D, Bolin R, Dunne SF, Balakrishnan S, Camarda R, Roth D, Zielinski-Mozny NA, Yau C, Vassilopoulos A, Huang TH, Kim KA, Horiuchi D. Begg LR, et al. Among authors: horiuchi d. Commun Med (Lond). 2024 Feb 20;4(1):22. doi: 10.1038/s43856-024-00444-8. Commun Med (Lond). 2024. PMID: 38378783 Free PMC article.
80 results